Federal watchdog highlights flaws in speedy FDA approvals

One-third of the drugs granted an accelerated approval from the Food and Drug Administration haven’t completed trials to confirm their potential benefits, an internal government watchdog reported Thursday in a report that highlighted the flaws in the 30-year-old program meant to speed new medicines for rare and deadly diseases to market.